Santalis Pharmaceuticals, Inc. is a joint venture with TFS Corporation of Australia (ASX: TFC), the world's leader in sustainable sandalwood oil (EISO) supply. TFS has granted Santalis worldwide exclusive rights to ESIO for healthcare use and the company is leveraging this high value botanical drug candidate to develop a unique, evidence-based platform of highly differentiated retail, OTC and Rx botanical healthcare products. Areas of research and clinical interest include acne, rosacea, eczema, skin cancer and drug resistant infections such as MRSA and Clostridium difficule. Santalis launched its first range of OTC acne products in late 2015, in the US under Galderma's Benzac® Brand. 

TFS to acquire US pharmaceutical partners to capture downstream revenues from product sales.

Santalis was acquired by TFS Corporation Ltd. (ASX:TFC) in June 2015